[A21-36] Pembrolizumab (colorectal cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.07.2021
Commission awarded on 01.04.2021 by the Federal Joint Committee (G-BA).
First-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer
- Patients for whom intensive therapy is appropriate: hint of considerable added benefit.
- Patients for whom intensive therapy is not appropriate: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.